EZH2 and Miyoshi myopathy: Notably, co-inhibition of EZH2 and DNMTs significantly reduced viability compared to single-agent treatment across a panel of MM cell lines (Fig. 7b-e) and demonstrated a positive Bliss score, suggesting that the effect of the drug combination surpasses the expected effect, indicating synergy (Supplementary Fig. 8).